Intensified dose-dense neoadjuvant chemotherapy using paclitaxel-gemcitabine and docetaxel-doxorubicin combinations for locally advanced breast cancer

Abstract

The developed chemotherapy (CT) regimen with paclitaxel and gemcitabine with the interval being reduced between the cycles up to 2 weeks can shorten the time of preoperative treatment 1.5-fold and may be further investigated in the neoadjuvant CT for inoperable breast cancer. Intensified CT in the regimen of paclitaxel 175 mg/m2 one day, gemcitabine 2000 mg/m2 one day, docetaxel 70 mg/m2 one day + doxorubi- cin 60 mg/m2 one day + colony-stimulating factors every 2 weeks has a high clinical effectiveness and a satisfactory tolerability.

Keywords

• locally advanced breast cancer
• dose-dense chemotherapy
• paclitaxel
• gemcitabine
• docetaxel
• doxorubicin
• neoadjuvant chemotherapy